---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-054711"
form_type: "8-K"
ticker: "QTTB"
cik: "0001661998"
company_name: "Q32 Bio Inc."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:26:49.106410+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Q32 Bio raises $10.5M in registered direct offering to fund bempikibart trials

## Summary
- Gross proceeds of ~$10.5M from 1,666,679 common shares and pre-funded warrants for 1,025,654 shares at $3.90/share.
- Offering price equals Feb 13 closing price; pre-funded warrants exercisable at $0.0001/share.
- Net proceeds for working capital, including advancing bempikibart for alopecia areata into future trials.
- Closing expected Feb 18, 2026; led by new institutional investor with participation from existing investor.

## SEC filing metadata
- accession: 0001193125-26-054711
- form_type: 8-K
- ticker: QTTB
- cik: 0001661998
- company_name: Q32 Bio Inc.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661998/000119312526054711/0001193125-26-054711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661998/000119312526054711/d113308d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-054711
- JSON: https://secwatch.observer/filing/0001193125-26-054711.json
- Plain text: https://secwatch.observer/filing/0001193125-26-054711.txt

## Key facts
- Material Agreements
  Q32 Bio Inc. entered into Purchase Agreement with certain institutional investors valued at approximately $10.5 million (effective 2026-02-17).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional investors
  - Value: approximately $10.5 million
  - Effective: 2026-02-17
  source text: On February 17, 2026, Q32 Bio Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors relating to the issuance and sale of (i) 1,666,679 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $3.90 per share, and (ii) pre-funded warrants to purchase 1,025,654 shares of Common Stock (the “Pre-Funded Warrants”), to such investors in a registered direct offering (the “Offering”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661998/000119312526054711/0001193125-26-054711-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.